Want to see NAMS full AI Analyst Report?
NewAmsterdam Pharma Company (NAMS) Income Statement
NewAmsterdam Pharma Company Income Statement
Last quarter (Q2 2026), NewAmsterdam Pharma Company's total revenue was $3.70M, a decrease of 80.67% from the same quarter last year. In Q2, NewAmsterdam Pharma Company's net income was $-64.14M. See NewAmsterdam Pharma Company’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| $ 22.50M | $ 45.56M | $ 14.09M | $ 102.69M | $ 0.00 | |
| $ 22.44M | $ 45.56M | $ 14.09M | $ 102.69M | $ 0.00 | |
| $ 248.13M | $ 221.85M | $ 197.06M | $ 106.25M | $ 34.98M | |
| Depreciation and Amortization | $ 220.00K | $ 113.00K | $ 49.00K | $ 9.00K | $ 5.00K |
| $ -242.32M | $ -241.49M | $ -176.86M | $ -22.34M | $ -41.37M | |
| $ -225.68M | $ -176.29M | $ -182.97M | $ -3.56M | $ -34.98M | |
| $ 21.86M | $ -65.31M | $ 6.06M | $ -19.08M | $ -6.81M | |
| $ -203.82M | $ -241.60M | $ -176.91M | $ -22.63M | $ -41.78M | |
| $ -203.82M | $ -241.60M | $ -176.94M | $ -22.63M | $ -41.78M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.75 | $ -2.56 | $ -2.15 | $ -1.19 | $ -3.34 |
| Diluted EPS | $ -1.75 | $ -2.56 | $ -2.15 | $ -1.19 | $ -3.34 |
| Weighted Average Shares Outstanding | 114.40M | 94.36M | 82.16M | 18.97M | 17.75M |
| Weighted Average Shares Outstanding (Diluted) | 114.40M | 94.36M | 82.16M | 18.97M | 17.75M |
Currency in USD
